Pre-hospital fibrinolysis in the management of patients with ST elevation acute coronary syndrome: Review of the evidence, implementation and future directions

A. C. Camuglia, S. Allen Luis, A. Sengupta, J. H.N. Bett, D. L. Walters

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Time to reperfusion is among the strongest predictors of clinical outcome in patients who present with ST elevation acute myocardial infarction. When time to access is equivalent, primary percutaneous coronary intervention has demonstrated superior outcomes to fibrinolysis. However, where significant delays exist in accessing percutaneous intervention, fibrinolysis has an important role. The potential for fibrinolysis delivery in the pre-hospital setting means that delays to primary percutaneous intervention need to be considered from the time that the patient becomes eligible for fibrinolysis in the field. This can be particularly challenging in patients with symptom duration ofless than two hours, as some evidence suggests fibrinolysis may be particularly beneficial in this early phase. Additionally, access to primary percutaneous intervention provided by an experienced operator, in a timely manner at any time of the day or night, is not an available option in many healthcare settings. This review focuses on the current evidence and practice of pre-hospital fibrinolysis and assesses potential roles for this therapy in the future.

Original languageEnglish (US)
Pages (from-to)243-255
Number of pages13
JournalCardiovascular and Hematological Disorders - Drug Targets
Volume13
Issue number3
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Fibrinolysis
Acute Coronary Syndrome
Percutaneous Coronary Intervention
Reperfusion
Direction compound
Delivery of Health Care

Keywords

  • Acute myocardial infarction
  • Facilitated percutaneous coronary intervention
  • Pre-hospital fibrinolysis
  • Pre-hospital thrombolysis
  • Primary percutaneous coronary intervention

ASJC Scopus subject areas

  • Molecular Medicine
  • Hematology
  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Pre-hospital fibrinolysis in the management of patients with ST elevation acute coronary syndrome : Review of the evidence, implementation and future directions. / Camuglia, A. C.; Luis, S. Allen; Sengupta, A.; Bett, J. H.N.; Walters, D. L.

In: Cardiovascular and Hematological Disorders - Drug Targets, Vol. 13, No. 3, 01.01.2013, p. 243-255.

Research output: Contribution to journalReview article

@article{75620971b8f34d5d91badf99f2446b93,
title = "Pre-hospital fibrinolysis in the management of patients with ST elevation acute coronary syndrome: Review of the evidence, implementation and future directions",
abstract = "Time to reperfusion is among the strongest predictors of clinical outcome in patients who present with ST elevation acute myocardial infarction. When time to access is equivalent, primary percutaneous coronary intervention has demonstrated superior outcomes to fibrinolysis. However, where significant delays exist in accessing percutaneous intervention, fibrinolysis has an important role. The potential for fibrinolysis delivery in the pre-hospital setting means that delays to primary percutaneous intervention need to be considered from the time that the patient becomes eligible for fibrinolysis in the field. This can be particularly challenging in patients with symptom duration ofless than two hours, as some evidence suggests fibrinolysis may be particularly beneficial in this early phase. Additionally, access to primary percutaneous intervention provided by an experienced operator, in a timely manner at any time of the day or night, is not an available option in many healthcare settings. This review focuses on the current evidence and practice of pre-hospital fibrinolysis and assesses potential roles for this therapy in the future.",
keywords = "Acute myocardial infarction, Facilitated percutaneous coronary intervention, Pre-hospital fibrinolysis, Pre-hospital thrombolysis, Primary percutaneous coronary intervention",
author = "Camuglia, {A. C.} and Luis, {S. Allen} and A. Sengupta and Bett, {J. H.N.} and Walters, {D. L.}",
year = "2013",
month = "1",
day = "1",
doi = "10.2174/1871529X1303140129155809",
language = "English (US)",
volume = "13",
pages = "243--255",
journal = "Cardiovascular and Hematological Disorders - Drug Targets",
issn = "1871-529X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Pre-hospital fibrinolysis in the management of patients with ST elevation acute coronary syndrome

T2 - Review of the evidence, implementation and future directions

AU - Camuglia, A. C.

AU - Luis, S. Allen

AU - Sengupta, A.

AU - Bett, J. H.N.

AU - Walters, D. L.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Time to reperfusion is among the strongest predictors of clinical outcome in patients who present with ST elevation acute myocardial infarction. When time to access is equivalent, primary percutaneous coronary intervention has demonstrated superior outcomes to fibrinolysis. However, where significant delays exist in accessing percutaneous intervention, fibrinolysis has an important role. The potential for fibrinolysis delivery in the pre-hospital setting means that delays to primary percutaneous intervention need to be considered from the time that the patient becomes eligible for fibrinolysis in the field. This can be particularly challenging in patients with symptom duration ofless than two hours, as some evidence suggests fibrinolysis may be particularly beneficial in this early phase. Additionally, access to primary percutaneous intervention provided by an experienced operator, in a timely manner at any time of the day or night, is not an available option in many healthcare settings. This review focuses on the current evidence and practice of pre-hospital fibrinolysis and assesses potential roles for this therapy in the future.

AB - Time to reperfusion is among the strongest predictors of clinical outcome in patients who present with ST elevation acute myocardial infarction. When time to access is equivalent, primary percutaneous coronary intervention has demonstrated superior outcomes to fibrinolysis. However, where significant delays exist in accessing percutaneous intervention, fibrinolysis has an important role. The potential for fibrinolysis delivery in the pre-hospital setting means that delays to primary percutaneous intervention need to be considered from the time that the patient becomes eligible for fibrinolysis in the field. This can be particularly challenging in patients with symptom duration ofless than two hours, as some evidence suggests fibrinolysis may be particularly beneficial in this early phase. Additionally, access to primary percutaneous intervention provided by an experienced operator, in a timely manner at any time of the day or night, is not an available option in many healthcare settings. This review focuses on the current evidence and practice of pre-hospital fibrinolysis and assesses potential roles for this therapy in the future.

KW - Acute myocardial infarction

KW - Facilitated percutaneous coronary intervention

KW - Pre-hospital fibrinolysis

KW - Pre-hospital thrombolysis

KW - Primary percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=84893458493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893458493&partnerID=8YFLogxK

U2 - 10.2174/1871529X1303140129155809

DO - 10.2174/1871529X1303140129155809

M3 - Review article

C2 - 24479721

AN - SCOPUS:84893458493

VL - 13

SP - 243

EP - 255

JO - Cardiovascular and Hematological Disorders - Drug Targets

JF - Cardiovascular and Hematological Disorders - Drug Targets

SN - 1871-529X

IS - 3

ER -